1. Home
  2. SYBX vs NAII Comparison

SYBX vs NAII Comparison

Compare SYBX & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYBX
  • NAII
  • Stock Information
  • Founded
  • SYBX N/A
  • NAII 1980
  • Country
  • SYBX United States
  • NAII United States
  • Employees
  • SYBX N/A
  • NAII N/A
  • Industry
  • SYBX Biotechnology: Pharmaceutical Preparations
  • NAII Medicinal Chemicals and Botanical Products
  • Sector
  • SYBX Health Care
  • NAII Health Care
  • Exchange
  • SYBX Nasdaq
  • NAII Nasdaq
  • Market Cap
  • SYBX 20.0M
  • NAII 21.2M
  • IPO Year
  • SYBX N/A
  • NAII 1987
  • Fundamental
  • Price
  • SYBX $1.75
  • NAII $3.22
  • Analyst Decision
  • SYBX
  • NAII
  • Analyst Count
  • SYBX 0
  • NAII 0
  • Target Price
  • SYBX N/A
  • NAII N/A
  • AVG Volume (30 Days)
  • SYBX 50.2K
  • NAII 40.8K
  • Earning Date
  • SYBX 11-11-2025
  • NAII 11-12-2025
  • Dividend Yield
  • SYBX N/A
  • NAII N/A
  • EPS Growth
  • SYBX N/A
  • NAII N/A
  • EPS
  • SYBX N/A
  • NAII N/A
  • Revenue
  • SYBX N/A
  • NAII $134,440,000.00
  • Revenue This Year
  • SYBX N/A
  • NAII N/A
  • Revenue Next Year
  • SYBX N/A
  • NAII N/A
  • P/E Ratio
  • SYBX N/A
  • NAII N/A
  • Revenue Growth
  • SYBX N/A
  • NAII 19.00
  • 52 Week Low
  • SYBX $0.90
  • NAII $2.57
  • 52 Week High
  • SYBX $1.96
  • NAII $4.70
  • Technical
  • Relative Strength Index (RSI)
  • SYBX 49.98
  • NAII 62.00
  • Support Level
  • SYBX $1.52
  • NAII $2.77
  • Resistance Level
  • SYBX $1.86
  • NAII $3.39
  • Average True Range (ATR)
  • SYBX 0.12
  • NAII 0.21
  • MACD
  • SYBX -0.01
  • NAII 0.06
  • Stochastic Oscillator
  • SYBX 42.86
  • NAII 75.37

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About NAII Natural Alternatives International Inc.

Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.

Share on Social Networks: